Skip to content

Giving Information on the Risks and Limitations of Mammography Screening (GIRLS)

Giving Information on the Risks and Limitations of Mammography Screening (GIRLS): a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02914197
Acronym
GIRLS
Enrollment
608
Registered
2016-09-26
Start date
2017-11-20
Completion date
2019-11-30
Last updated
2018-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm

Keywords

Decision, Mammography, Informed Choice, Full Information, Decision Aid, Self-efficacy, Shared decision making, Over-detection, Over-diagnosis

Brief summary

To trial the provision of full information on the benefits and risks of mammography in women that are eligible for breast screening. The knowledge many women have of mammography is not reflective of the recent change in evidence; it is often missing information on over-diagnosis and over-detection. Women tend to overestimate their risk of breast cancer and the benefits of breast screening. In addition, universal breast screening programs are biased towards emphasizing screening. However, a mammogram is not a perfect test and there is no right or wrong decision about whether to have a screening mammogram. It is an individual woman's decision to make. To understand the effect of changing information to reflect the potential for over-diagnosis and over-treatment, we will carry out a pragmatic controlled trial of implementation of balanced information on mammography in family practice.

Detailed description

1:1 double-blinded randomized controlled trial of patients to receive the intervention or standard information (control) at the study start in an information package. The intervention includes a decision aid (previously developed by Hersch et al. 2015, with minor modifications to reflect the Canadian context), a YouTube video link and an invitation to attend a group information session. The intervention or standard information, depending on participants assigned study group, will be mailed or emailed to participants. The information packages will also include questionnaires to collect data on outcome measures. There will be two study waves to account for women's eligibility at different time points (i.e. when approaching a mammogram due date). The first wave of participants will receive their information package at the study start and the second wave of participants will be sent their information packages 6 months after the study start. Each wave of participants will be followed for one year. Data collection will include quantitative measures of factors relevant to the decision-making process. Screening participant rates will be measured for each wave of participants, 6 months and 12 months after their respective enrollment date. Qualitative methods will be used to obtain an understanding of clinician's perception of decision aids in a primary care setting. Outcome measures and analyses will be blinded.

Interventions

OTHERFull information

Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.

Sponsors

David Braley and Nancy Gordon Chair in Family Medicine
CollaboratorOTHER
McMaster University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
47 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* Patient on the active roster of physicians of MUSIC (McMaster University Sentinel and Information Collaboration; McMaster Family Health Team). * Due for a mammogram (have not had a mammogram ≥ 18 months) according to Canadian screening interval recommendations for routine screening.

Exclusion criteria

* Previous history of invasive or non-invasive breast cancer. * At higher risk for breast cancer compared to the general population i.e. identified as having the BRCA1 or BRCA2 gene, immediate family member has had breast cancer. * Have had a mammogram within the last 18 months (\< 18 months).

Design outcomes

Primary

MeasureTime frameDescription
Self-efficacy1 monthDecision Self-Efficacy Scale

Secondary

MeasureTime frameDescription
Informed Choice (Attitude)1 monthInformed choice is comprised of knowledge, attitudes and intention/decisions. Informed choice will be measured using intention to screen at the first data collection point and screening participation at the second and third data collection point. Attitudes will be measured using the Multidimensional Measure of Informed Choice (MMIC).
Informed Choice (Intention)1 monthInformed choice is comprised of knowledge, attitudes and intention/decisions. Informed choice will be measured using intention to screen at the first data collection point and screening participation at the second and third data collection point. Intention to screen will be measured using a 5-point Likert scale.
Decisional Conflict1 monthSURE (Decisional Conflict Scale- SURE Test for clinical practice)
Anxiety1 monthWomen will be asked about their anxiety towards participating in breast screening after reading their information pamphlet using a 4-point Likert scale.
Trust in Medical System1 monthMMI (Medical Mistrust Index)
Informed Choice (Knowledge)1 monthInformed choice is comprised of knowledge, attitudes and intention/decisions. Informed choice will be measured using intention to screen at the first data collection point and screening participation at the second and third data collection point. Knowledge will be measured using the Multidimensional Measure of Informed Choice (MMIC).
Information Relevant to the Decision Making Process1 monthWomen will be asked to describe the information that was relevant to their individual decision making process.
Decision Regret12 monthDecision Regret Scale
Screening Participation6 months and 12 monthsData on a women's decision to undergo screening through mammography will be obtained from patient's electronic medical record.
Acceptance of a Decision Aid in Primary Care12 monthsClinician staff will be asked to list the five best things and five worst things about the implementation of a patient focused decision aid.
Knowledge of the Benefits and Risks of Mammography1 monthMultiple choice question on knowledge of breast cancer mortality reduction and over-diagnosis.
Perception of Health Provider Recommendation1 monthWomen will be asked to assess their perception of the strength of the recommendation that their health care provider makes with respect to breast screening.

Countries

Canada

Contacts

Primary ContactDee Mangin, MBChB, DPH, FRNZCGP
mangind@mcmaster.ca905-525-9140
Backup ContactJessica Langevin, MPH
langevjn@mcmaster.ca905-525-9140

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026